SCHEMBL633227

SCHEMBL633227

COc1c(F)ccc(N)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 1/20 0.37
ALDH1A1 P00352 6/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP3A4 P08684 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
TSHR P16473 1/20 0.35
ALOX5AP P20292 3/20 0.33
FEN1 P39748 3/20 0.33
KDM4E B2RXH2 2/20 0.33
IDO1 P14902 1/20 0.33
ADRA2B P18089 1/20 0.33
PTGS1 P23219 1/20 0.33
MAPT P10636 1/20 0.33
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
BACE1 P56817 1/20 0.33
EP300 Q09472 1/20 0.32
KAT8 Q9H7Z6 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12074163 0.86 ALOX5AP (0.39) ALDH1A1HSD17B10CYP3A4TDP1TSHR
SCHEMBL23829848 0.84 ALDH1A1 (0.37) MEP1BALDH1A1HSD17B10CYP3A4TDP1
SCHEMBL29398924 0.82 ALOX5AP (0.37) ALDH1A1HSD17B10CYP3A4TDP1TSHR
SCHEMBL1707536 0.82 ALOX5AP (0.37) ALDH1A1HSD17B10CYP3A4TDP1TSHR
SCHEMBL1994314 0.80 MEP1B (0.41) MEP1BALDH1A1HSD17B10KDM4EMAPK1
SCHEMBL1766161 0.80 IDO1 (0.45) ALDH1A1HSD17B10CYP3A4TDP1TSHR
SCHEMBL13862135 0.80 TUBB4A (0.39) ALDH1A1HSD17B10CYP3A4TDP1TSHR
SCHEMBL22833321 0.80 CYP3A4 (0.37) MEP1BALDH1A1HSD17B10CYP3A4TDP1
SCHEMBL6736261 0.78 ALDH1A1 (0.41) MEP1BALDH1A1HSD17B10CYP3A4TDP1
SCHEMBL3273426 0.78 ALOX5AP (0.35) MEP1BALDH1A1HSD17B10CYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3837241-B1 FLUORO SS-CARBOLINE COMPOUNDS FOR THE TREATMENT OF BONE HOMEOSTASIS OSSIFI THERAPEUTICS LLC (US) 2026-04-22 EP disclosed
US-20260097041-A1 FLUORO BETA-CARBOLINE COMPOUNDS OSSIFI THERAPEUTICS LLC (US) 2026-04-09 US disclosed
US-12324809-B2 Fluoro beta-carboline compounds OSSIFI THERAPEUTICS LLC (US) 2025-06-10 US disclosed
US-20250025472-A1 FLUORO BETA-CARBOLINE COMPOUNDS OSSIFI THERAPEUTICS LLC 2025-01-23 US disclosed
CN-114026073-B Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders ARRAY生物制药公司 2024-08-23 CN disclosed
US-20240270762-A1 PENICILLIN-BINDING PROTEIN INHIBITORS SPRING MILL PHARMA, INC. 2024-08-15 US disclosed
CN-113646049-B Pyrimidinone derivatives as SHP2 antagonists 默克专利有限公司 2024-08-13 CN disclosed
CN-118044519-A Molecules having pesticidal utility, and intermediates, compositions and methods related thereto 科迪华农业科技有限责任公司 2024-05-17 CN disclosed
US-20240124422-A1 MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED 2024-04-18 US disclosed
EP-4347607-A1 PENICILLIN-BINDING PROTEIN INHIBITORS Venatorx Pharmaceuticals, Inc. (US) 2024-04-10 EP disclosed
US-20110190260-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2011-08-04 US disclosed
WO-2011001114-A1 NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS SANOFI-AVENTIS (FR) 2011-01-06 WO disclosed
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
EP-2205317-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES Senexis Limited (GB) 2010-07-14 EP disclosed
WO-2010010188-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. GALAPAGOS NV (BE) 2010-01-28 WO disclosed
WO-2010010190-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2010-01-28 WO disclosed
EP-2076497-A1 AMINOMETHYL-4-IMIDAZOLES F. Hoffmann-Roche AG (CH) 2009-07-08 EP disclosed
WO-2009044160-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2009-04-09 WO disclosed
US-20080119535-A1 AMINOMETHYL-4-IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2008-05-22 US disclosed
WO-2008046757-A1 AMINOMETHYL-4-IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250025472-A1 FLUORO BETA-CARBOLINE COMPOUNDS GLS, AFF1, SLC5A1 MEP1B 2027/4885ALDH1A1 388/4885HSD17B10 2933/4885
US-20260097041-A1 FLUORO BETA-CARBOLINE COMPOUNDS CTNNB1, SLC5A1, SLC5A2 MEP1B 3071/4885ALDH1A1 1792/4885HSD17B10 4366/4885
US-20080119535-A1 AMINOMETHYL-4-IMIDAZOLES INMT, HTR4, MC4R MEP1B 1363/4885ALDH1A1 631/4885HSD17B10 1504/4885
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HCRTR1, HCRTR2, RTN3 MEP1B 2956/4885ALDH1A1 4039/4885HSD17B10 1345/4885
US-20110190260-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES TRAF6, IL6, TLR6 MEP1B 3330/4885ALDH1A1 2075/4885HSD17B10 3965/4885
US-20240124422-A1 MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS PIK3CA, PIK3CD, PIK3R5 MEP1B 348/4885ALDH1A1 2823/4885HSD17B10 1733/4885
US-20240270762-A1 PENICILLIN-BINDING PROTEIN INHIBITORS PEPD, BPGM, EBPL MEP1B 325/4885ALDH1A1 2794/4885HSD17B10 2285/4885
US-12324809-B2 Fluoro beta-carboline compounds GLS, AFF1, SLC5A1 MEP1B 2027/4885ALDH1A1 388/4885HSD17B10 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.